IMMUNOVANT INC. - COMMON STOCK

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023

22 May 2023 06:00:00 By Nasdaq GlobeNewswire

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022

03 Feb 2023 06:00:00 By Nasdaq GlobeNewswire

Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th

07 Nov 2022 07:00:01 By Nasdaq GlobeNewswire

Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock

04 Oct 2022 07:45:00 By Nasdaq GlobeNewswire

Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn  

28 Sep 2022 09:45:00 By Nasdaq GlobeNewswire

Immunovant to Present at Roivant Investor Day on September 28th

21 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th

09 Sep 2022 07:00:00 By Nasdaq GlobeNewswire

UPDATE -- Immunovant Announces Two New Development Programs for Batoclimab

07 Sep 2022 06:11:44 By Nasdaq GlobeNewswire

Immunovant Announces Two New Development Programs for Batoclimab

07 Sep 2022 05:30:00 By Nasdaq GlobeNewswire

Immunovant to Host Investor Webcast to Announce Two New Indications for Batoclimab on September 7, 2022

24 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended June 30, 2022

05 Aug 2022 06:00:00 By Nasdaq GlobeNewswire

Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022

08 Jun 2022 06:00:01 By Nasdaq GlobeNewswire

Immunovant to Report Fourth Quarter and Full Year 2022 Financial Results on June 8, 2022

06 Jun 2022 15:47:47 By Nasdaq GlobeNewswire

Immunovant to Present at the H.C. Wainwright Global Investment Conference on May 25th

23 May 2022 15:05:00 By Nasdaq GlobeNewswire

Immunovant to Present at the UBS Global Healthcare Conference on May 23rd

19 May 2022 15:05:00 By Nasdaq GlobeNewswire

Immunovant to Present at LifeSci Partners’ Immunology and Inflammation Symposium on May 10th

04 May 2022 07:00:02 By Nasdaq GlobeNewswire

Immunovant to Host Virtual R&D Day on March 30, 2022

28 Mar 2022 06:00:00 By Nasdaq GlobeNewswire

Immunovant to Present at the 11th Annual SVB Leerink Global Healthcare Conference

09 Feb 2022 07:00:01 By Nasdaq GlobeNewswire

Immunovant Reports Financial Results for the Quarter Ended December 31, 2021

04 Feb 2022 06:00:00 By Nasdaq GlobeNewswire

Immunovant Appoints Mark Levine as Chief Legal Officer

25 Jan 2022 07:30:00 By Nasdaq GlobeNewswire